Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain and A1-C2 domain interface

Department of Biochemistry and Biophysics, University of Rochester School of Medicine, Rochester, NY, USA.
Journal of Thrombosis and Haemostasis (Impact Factor: 5.72). 12/2011; 10(3):492-5. DOI: 10.1111/j.1538-7836.2011.04597.x
Source: PubMed
Download full-text


Available from: Hironao Wakabayashi, Jul 21, 2014
17 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein design or redesign generate an amino acid sequence that folds to a stable protein and performs a desired function. In other words, designer proteins are modified versions of naturally occurring proteins. The engineering, design and selection of proteins for use in therapy and biotechnology is essential. Protein design has become a powerful approach for understanding the relationship between amino acid sequence and 3-dimensional structure. Moreover, protein design challenges have direct relevance for biomedicine. Designer proteins may help produce more drugs with longer shelf-life. Researchers are developing new methods to create ‘tailor-made’ peptides and proteins with improved pharmacological properties
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Proteolytic cleavage of factor VIII (FVIII) to activated FVIIIa is required for participation in the coagulation cascade. The A2 domain is no longer covalently bound in the resulting activated heterotrimer and is highly unstable. Aspartic acid (D) 519 and glutamic acid (E) 665 at the A1-A2 and A2-A3 domain interfaces were identified as acidic residues in local hydrophobic pockets. Replacement with hydrophobic valine (V; D519V/E665V) improved the stability and activity of the mutant FVIII over the wild-type (WT) protein in several in vitro assays. In the current study, we examined the impact of mutations on secondary and tertiary structure as well as in vivo stability, pharmacokinetics (PK), efficacy, and immunogenicity in a murine model of Hemophilia A (HA). Biophysical characterization was performed with far-UV circular dichroism (CD) and fluorescence emission studies. PK and efficacy of FVIII was studied following i.v. bolus doses of 4, 10 and 40 IU/kg with chromogenic and tail clip assays. Immunogenicity was measured with the Bethesda assay and ELISA after a series of i.v. injections. Native secondary and tertiary structure was unaltered between variants. PK profiles were similar at higher doses, but at 4 IU/kg plasma survival of D519V/E665V was improved. Hemostasis at low concentrations was improved for the mutant. Immune response was similar between variants. Overall, these results demonstrate that stabilizing mutations in the A2 domain of FVIII can improve HA therapy in vivo.
    The AAPS Journal 06/2014; 16(5). DOI:10.1208/s12248-014-9627-2 · 3.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An important negative regulator of factor VIIIa (FVIIIa) cofactor activity is A2 subunit dissociation. FVIII molecules with stabilized activity have been generated by elimination of charged residues at the A1-A2 and A2-A3 interfaces. These molecules exhibited reduced decay rates as part of the enzymatic factor Xa generation complex (FXase) and retained their activities under thermal and chemical denaturing conditions. We describe here the potency and efficacy of one such stability variant, D519V/E665V, derived from B-domain-deleted FVIII (BDD-FVIII). The major effect of A2 stabilization was on cofactor activity. D519V/E665V potency was increased 2-fold by the 2-stage chromogenic assay relative to BDD-FVIII. D519V/E665V demonstrated enhanced thrombin generation responses (5-fold by peak thrombin) relative to BDD-FVIII. In vivo consequences of enhanced cofactor activity of D519V/E665V included >4-fold increased maximal platelet-fibrin deposition after laser injury and 2-fold increased protection from bleeding in an acute prolonged vascular injury model in hemophilia A mice. These results demonstrate that noncovalent stabilization of the FVIII A2 subunit can prolong its cofactor activity, leading to differential enhancement in clot formation over protection from blood loss in hemophilia. The FVIII molecule described here is the first molecule with clear efficacy enhancement due to noncovalent stabilization of the A2 domain.
    Blood 11/2014; 125(2). DOI:10.1182/blood-2014-02-555656 · 10.45 Impact Factor